Dupixent, Regeneron and FDA
Regeneron, Sanofi Get New FDA Review of Dupixent for CSU
The FDA last year turned away the companies' application and asked for additional efficacy data. Regeneron and Sanofi said the resubmission adds results from an additional Phase 3 study of Dupixent in CSU, which causes sudden and debilitating hives and recurring itch.
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...
Earlier in 2019 Sanofi also paid Regeneron $462 million to exit from an immuno-oncology alliance formed in 2015, and in 2017 said they would end discovery research in new antibody drugs.
An eczema drug jointly developed by pharmaceutical companies Regeneron and Sanofi continues to stand above all comers ...
2 Top Growth Stocks to Buy on the Dip was originally published by The Motley Fool ...
Regeneron released a strong financial report for Q3 and was the 15th of 16 in the last four years. Read why I upgrade REGN ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback